title: Naringenin is an inhibitor of human serum paraoxonase (PON1): an in vitro study.
abstract: BACKGROUND
  Inhibition studies on PON1 as an organophosphate-hydrolyzing and atheroprotective enzyme could be useful in elucidating the function of PON1. This study is aimed at examining the in vitro effects of the flavonoid naringenin on PON1 activity in human serum and purified enzyme.
  
  
  METHODS
  The inhibition kinetics of the interaction of naringenin with human PON1 in serum and purified enzyme was determined spectrophotometrically using paraoxon and phenylacetate as the substrates.
  
  
  RESULTS
  Naringenin could be introduced as an effective inhibitor on purified human PON1 activity for phenylacetate as the substrate with an IC(50) value of 10 µM. Paraoxonase and arylesterase activities of PON1, in the serum assay, were also inhibited by naringenin with IC(50) values of 37.9 and 34.6 µM, respectively. PON1, according to acompetitive-type inhibition pattern, was inhibited by naringenin with K(i) constant of 14.5 µM for serum paraoxonase activity. The results were compared with a known inhibitor of PON1, 2-hydroxyquinoline. We believe (to our knowledge) that this is the first reported study for kinetic parameters of PON1 inhibition by naringenin.
  
  
  CONCLUSIONS
  Lipophilic property appears to be an important feature of the structure in evaluating the inhibitor potential. Comparison of our findings and other authors showed that the induction of PON1 gene by naringenin and its inhibitory effects on the enzyme protein are probably two different mechanisms by which the flavonoid affects PON1. The in vitro data reported in this study could be useful in the development of structure-activity relationship for PON1 inhibition.
authors.affiliation: Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. kmahrooz@yahoo.com
authors.forename: Abdolkarim
authors.initials: A
authors.lastname: Mahrooz
authors.forename: Mohammad-Reza
authors.initials: MR
authors.lastname: Rashidi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Nouri
mesh_terms: D043303:Aryldialkylphosphatase / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism; D002265:Carboxylic Ester Hydrolases / Q000378:metabolism; D044950:Flavanones / Q000494:pharmacology*; D006801:Humans; D006912:Hydroxyquinolines / Q000378:metabolism; D010648:Phenylacetates / Q000378:metabolism
chemical_list: D044950:Flavanones; D006912:Hydroxyquinolines; D010648:Phenylacetates; C107724:2-hydroxyquinoline; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase; C025136:phenylacetic acid; C005273:naringenin
references.citation: Nat Struct Mol Biol. 2004 May;11(5):412-9
references.pmid: 15098021
references.citation: Coron Artery Dis. 2004 Aug;15(5):277-83
references.pmid: 15238825
references.citation: Phytochemistry. 2003 Jan;62(1):89-99
references.pmid: 12475624
references.citation: Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1248-50
references.pmid: 12171781
references.citation: Am J Hum Genet. 1983 Mar;35(2):214-27
references.pmid: 6301268
references.citation: Biosci Biotechnol Biochem. 2003 Dec;67(12):2548-55
references.pmid: 14730132
references.citation: Curr Opin Lipidol. 2005 Aug;16(4):393-9
references.pmid: 15990587
references.citation: Dig Dis Sci. 2007 Aug;52(8):2006-14
references.pmid: 17420940
references.citation: Ann N Y Acad Sci. 2002 May;957:321-4
references.pmid: 12074989
references.citation: Mol Cell Biol. 2004 Jun;24(12):5209-22
references.pmid: 15169886
references.citation: Chem Biol Interact. 1999 May 14;119-120:79-84
references.pmid: 10421441
references.citation: Annu Rev Med. 2003;54:371-92
references.pmid: 12525679
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):78-88
references.pmid: 14579013
references.citation: Free Radic Biol Med. 2006 Dec 15;41(12):1727-46
references.pmid: 17157175
references.citation: JAMA. 1996 Feb 14;275(6):447-51
references.pmid: 8627965
references.citation: Crit Rev Clin Lab Sci. 2009;46(2):83-106
references.pmid: 19255916
references.citation: Toxicol Appl Pharmacol. 2009 Feb 15;235(1):1-9
references.pmid: 19071155
references.citation: Pharmacol Ther. 2002 Nov-Dec;96(2-3):67-202
references.pmid: 12453566
references.citation: Bioorg Med Chem. 2002 Jul;10(7):2239-44
references.pmid: 11983521
references.citation: Bioorg Med Chem Lett. 2003 May 19;13(10):1623-6
references.pmid: 12729627
references.citation: J Clin Invest. 1998 Apr 15;101(8):1581-90
references.pmid: 9541487
references.citation: Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S
references.pmid: 15640486
references.citation: Clin Chim Acta. 2009 Dec;410(1-2):1-12
references.pmid: 19799889
references.citation: Z Naturforsch C J Biosci. 2004 Sep-Oct;59(9-10):726-33
references.pmid: 15540607
references.citation: Atherosclerosis. 2002 Feb;160(2):425-32
references.pmid: 11849667
references.citation: Biochem Biophys Res Commun. 2009 Feb 20;379(4):1001-4
references.pmid: 19141295
references.citation: Drug Metab Dispos. 2000 Nov;28(11):1335-42
references.pmid: 11038162
references.citation: Circulation. 1996 Dec 1;94(11):2720-7
references.pmid: 8941095
references.citation: Clin Chim Acta. 2002 Mar;317(1-2):181-90
references.pmid: 11814474
references.citation: Atheroscler Suppl. 2002 Dec;3(4):49-55
references.pmid: 12573363
references.citation: Am J Clin Nutr. 1998 Apr;67(4):624-30
references.pmid: 9537609
references.citation: Free Radic Biol Med. 2005 Jan 15;38(2):153-63
references.pmid: 15607899